Controversies in the Treatment of Early-Stage Hodgkin's Lymphoma

New England Journal of Medicine 372(17):1667 (2015) PMID 25901431

Hodgkin’s lymphoma affects about 8000 patients a year in the United States, and with available therapies, about 7000 of them will be cured. Although room for improvement still exists, recent clinical research has focused on determining how little therapy can be given to maintain the current high cure rates. The focus on cutting back therapy to the bare minimum is related to well-defined, treatment-related late toxic effects. The life-threatening or fatal toxic effects of radiation therapy include second cancers (including cancers of the breast, skin, thyroid, lung, and stomach) and premature coronary-artery disease. Life-threatening or fatal toxic effects of chemotherapy . . .

DOI: 10.1056/NEJMe1502888